WCLC 2025 - Posters & ePosters-EP.12.07 Using Online Continuing Medical Education to Identify Ongoing Gaps in Global Clinicians’ Understanding of HER2-Altered NSCLC

EP.12.07 Using Online Continuing Medical Education to Identify Ongoing Gaps in Global Clinicians’ Understanding of HER2-Altered NSCLC

Back to course

Pdf Summary

This study assessed global oncologists’ and pathologists’ knowledge and competencies regarding HER2-altered non-small cell lung cancer (NSCLC), an important though uncommon biomarker in precision oncology that influences treatment decisions. Using an online, text-based Continuing Medical Education (CME) survey with 20 multiple-choice questions, researchers evaluated clinicians’ understanding of HER2 alterations—including mutations, amplifications, and overexpression—and their ability to apply testing methodologies and clinical trial data in practice. The survey, conducted from August 2024 to July 2025, included responses from 143 oncologists and 59 pathologists worldwide.<br /><br />Findings revealed significant gaps in clinicians’ knowledge, especially concerning accurate testing approaches and the practical application of clinical trial results to treatment planning. While clinicians showed relatively better recognition of HER2 characteristics, critical deficits persisted in using this information to tailor patient care. Notably, global oncologists outperformed their U.S. counterparts across all assessed themes, suggesting earlier adoption of HER2-targeted strategies and greater integration into practice outside the U.S.<br /><br />These results highlight a crucial need for focused, practical educational interventions aiming to bridge the gap between scientific understanding and clinical application of HER2 biomarker knowledge in NSCLC. The authors emphasize regionally tailored education to address diverse practice environments and enhance personalized treatment decisions. Future educational initiatives will seek to measure the impact of such training on improving global clinical outcomes and closing ongoing knowledge gaps.<br /><br />Supported by an independent educational grant from Bayer, this work underscores the relative novelty of HER2 as a therapeutic target in NSCLC and calls for targeted CME efforts to help clinicians translate biomarker advancements into improved patient care worldwide.

Asset Subtitle

Michelle Worst

Meta Tag

Speaker Michelle Worst

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

HER2-altered NSCLC

non-small cell lung cancer

oncologists

pathologists

precision oncology

biomarker testing

clinical trial application

continuing medical education

global knowledge gaps

targeted therapy